# AffyImmune Therapeutics

Source: https://onco.cc/companies/affyimmune-therapeutics/  
OnCo record `affyimmune-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Massachusetts company making CAR-T cell therapy aimed at ICAM-1, a molecule that some solid tumours carry in large amounts. Its first product is being tested in anaplastic thyroid cancer.

## Summary

AffyImmune describes itself as a clinical-stage company developing affinity-tuned CAR-T cells directed at ICAM-1, engineered so that the cells can be monitored non-invasively during treatment (AffyImmune website). Its lead candidate, AIC100, is an ICAM-1-directed CAR-T therapy developed for anaplastic and advanced differentiated thyroid cancer (AffyImmune website). The company announced on 23 July 2024 that the FDA had granted AIC100 Regenerative Medicine Advanced Therapy (RMAT) designation in recurrent anaplastic thyroid cancer (AffyImmune website, news). It is based at 303 Wyman Street, Waltham, Massachusetts (AffyImmune website).

## Fields

- Kind: Company
- Last checked: 2026-11-05
- Also known as: AffyImmune; AffyImmune Therapeutics, Inc.
- Tags: car-t; solid-tumour-cell-therapy
- HQ: Waltham, MA
- Type: cell-therapy
- Website: https://affyimmune.com

## Sources

- AffyImmune website: https://affyimmune.com/

## Connected records

- cancers: [Anaplastic thyroid cancer](https://onco.cc/cancers/anaplastic-thyroid-cancer/), [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- people: [Cassian Yee](https://onco.cc/people/cassian-yee/)

---
JSON: https://onco.cc/api/v1/entities/affyimmune-therapeutics.json